Keros Therapeutics (KROS) Net Cash Flow (2019 - 2025)
Keros Therapeutics (KROS) posted Net Cash Flow of -$406.1 million for Q4 2025, down 12567.21% on a QoQ basis from $3.3 million in Q3 2025, and down 1488.37% year-over-year from $29.2 million in Q4 2024.
Keros Therapeutics (KROS) Net Cash Flow (2019 - 2025) Analysis & Trends
Keros Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$406.1 million for Q4 2025.
- Quarterly Net Cash Flow fell 1488.37% year-over-year to -$406.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$272.5 million (down 218.99% YoY) and the FY2025 annual result came in at -$272.5 million, down 218.99% from the prior year.
- Net Cash Flow was -$406.1 million for Q4 2025 at Keros Therapeutics, down from $3.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $160.6 million in Q1 2025 and bottomed at -$406.1 million in Q4 2025.
- A 5-year average of $1.1 million and a median of $900500.0 in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow jumped 5071.22% — and 2025, when it sank 1488.37%.
- Keros Therapeutics' Net Cash Flow stood at $8.7 million in 2021, then jumped by 355.84% to $39.6 million in 2022, then rose by 9.17% to $43.3 million in 2023, then slumped by 32.38% to $29.2 million in 2024, then sank by 1488.37% to -$406.1 million in 2025.
- Business Quant data shows KROS's Net Cash Flow at -$406.1 million in Q4 2025, $3.3 million in Q3 2025, and -$30.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Keros Therapeutics | 377.42 Mn | 90.02 Mn | - | -406.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -406.06 Mn |
| Dec 31, 2025 | -406.06 Mn |
| Sep 30, 2025 | 3.26 Mn |
| Sep 30, 2025 | 3.26 Mn |
| Jun 30, 2025 | -30.33 Mn |
| Jun 30, 2025 | -30.33 Mn |
| Mar 31, 2025 | 160.61 Mn |
| Mar 31, 2025 | 160.61 Mn |
| Dec 31, 2024 | 29.25 Mn |
| Dec 31, 2024 | 29.25 Mn |
| Sep 30, 2024 | 125.06 Mn |
| Sep 30, 2024 | 125.06 Mn |
| Jun 30, 2024 | -36.58 Mn |
| Jun 30, 2024 | -36.58 Mn |
| Mar 31, 2024 | 111.30 Mn |
| Mar 31, 2024 | 111.30 Mn |
| Dec 31, 2023 | 43.25 Mn |
| Dec 31, 2023 | 43.25 Mn |
| Sep 30, 2023 | -34.25 Mn |
| Sep 30, 2023 | -34.25 Mn |